Announcement no. 16/2008
To OMX Nordic Exchange Copenhagen and the press.
Copenhagen, 31 March, 2008
Exiqon A/S' share capital and total number of voting rights
Pursuant to Section 6 of executive order no. 226 of 15 March 2007 about issuers'
disclosure obligations, it is hereby announced that Exiqon A/S' entire share
capital on 28 December 2007 is DKK 29.991.338, nominal value, divided into
shares of DKK 1.00, nominal value, each. Every share of DKK 1.00, nominal value,
carries one vote. The total number of voting rights is 29.991.338.
For additional information please contact
Lars Kongsbak, CEO, tel +45 4566 0450 or +45 4090 2101 Hans Henrik
Chrois Christensen, CFO +45 4565 0953 or +45 4090 2131
About Exiqon
Exiqon's corporate mission is to combine leading-edge scientific expertise in
gene expression with our proprietary LNA™ technology. Exiqon's products,
services and scientific staff enable life science researchers to make
groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a
new approach to the diagnosis of cancer. Exiqon's products are based on patented
technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and
sensitive analysis of nucleic acids. Exiqon aims to expand the existing product
offering for research use as well as to develop new proprietary molecular
diagnostic products. Exiqon, through a number of recent initiatives, has
positioned itself as a significant player in applying miRNA as the key biomarker
in cancer diagnostics.
Disclaimer
Forward-looking statements:
This announcement contains forward-looking statements regarding Exiqon's
potential future development and financial performance and other statements
which are not historical facts. Such statements are made on the basis of
assumptions and expectations which, to the best of Exiqon's knowledge, are
reasonable and well-founded at this time, but which may prove to be erroneous.
Exiqon's operations are characterized by the fact that its actual results may
deviate significantly from that described herein as anticipated, believed,
estimated or expected.
Exiqon A/S Bygstubben 9 Tel.: +45 45 66 08 E-mail: exiqon@exiqon.com
88
CVR.: 18 98 44 31 DK-2950 - Fax: +45 45Website: www.exiqon.com
- 66 18
- 88
-
-
k